The distribution of tissue fibronectin and sialic acid in human breast cancer

Cancer Biochemistry Biophysics

Volumn 16, Issue 1, 1997, Pages 63-70

  Suer S ^a   Baloglu H ^b   Gungor Z ^a   Sonmez H ^a   Kokoglu E ^a  

^a ISTANBUL UNIVERSITY   (Turkey)

^b GULHANE SCHOOL OF MEDICINE   (Turkey)

Author keywords

Breast cancer; Fibronectin; Sialic acid; Tumor marker

Indexed keywords

FIBRONECTIN; MEMBRANE PROTEIN; N ACETYLNEURAMINIC ACID;

ADULT; AGED; ARTICLE; BREAST TUMOR; COMPARATIVE STUDY; FEMALE; HUMAN; METABOLISM; MIDDLE AGED; PATHOLOGY; PHOTOMETRY; TISSUE DISTRIBUTION;

ADULT; AGED; BREAST NEOPLASMS; FEMALE; FIBRONECTINS; HUMANS; MEMBRANE PROTEINS; MIDDLE AGED; N-ACETYLNEURAMINIC ACID; NEPHELOMETRY AND TURBIDIMETRY; TISSUE DISTRIBUTION;

EID: 0032083314     PISSN: 03057232     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (47)

1. Alberts B., D Bray, J. Lewis, M. Raff, K. Roberts and J. O. Watson (1994). Molecular Biology of The Cell. (3 Ed). Garland Publishing. New York, pp. 986-988.
2. Blumenstock F. A., M. McKneally and T. M. Saba (1978). Quantification of immunoreactive opsonic alpha-2-surface binding (2-SB) glycoprotein in lung cancer patients. J. Reticuloendothel. Soc. Abstr. Suppl., 24, 18a.
3. Boccardo F., D. Guarneri, S. Zanardi, P. Castellani, L. Borsi and L. Zardi (1986). Fibronectin concentration in the plasma of patients with malignant and benign breast disease. Cancer Lett., 33, 317-323.
4. Choate J. J. and D. F. Mosher (1983). Fibronectin concentration in plasma of patients with breast cancer, colon cancer and acut leukemia. Cancer 51, 1142-1147.
5. Christensen L. (1992). The distribution of fibronectin, laminin and tetranectin in human breast cancer with special attention to the extracellular matrix. APMIS-Suppl., 26, 1-39.
6. Dnistrian A. and M. Schwartz (1981). Plasma lipid-bound sialic acid and carcinoembryonic antigen in cancer. Clin. Chem. 27, 1737-1739.
7. Eijan A. M., L. Puricelli, E. B. Joffe, D. Entin, D. Vuoto, E. Orlando and E. S. Lustig (1986). Serial analysis of fibronectin concentration in plasma of patients with benign and malignant breast diseases. Cancer 57, 1345-1349.
8. Evans I. M., R. Hiey, M. Murphy and B. Bosmann (1980). N. Acetylneuraminic acid transferase activity with growth of the R 3230 AL mammary tumor in rats and relationship of the serum activity to tumor burden. Cancer Res., 40, 3103-3111.
9. Feldman B. F., E. Brummerstedt, L. S. Larsen and S. M. Larsen (1988). Plasma fibronectin concentration associated with various types of canine neoplasia. Am. J. Vet. Res., 49, 1017-1019.
10. Gallurt P., P. Rodriguez, A. Lorenzo, J. J. Lopez-Saez, A. Senra and J. Millan (1992). Plasmatic fibronectin in malignancies. Int. J. Biol. Markers, 7, 240-243.
11. Gervais A. and E. Schuler (1991). Fibronectin in plasma and CSF: evidence for its intrathecal synthesis. J. Neurol. Sci., 105, 200-205.
12. Hayman E. G. and E. Ruoslahti (1979). Distribution of fetal bovine serum fibronectin and endogenous rat cell fibronectin in extracellular matrix. J. Cell. Biol., 83, 255-256.
13. Hayman E., E. Engvall and E. Ruoslahti (1981). Concommitant loss of cell surface fibronectin and laminin from transformed rat kidney cells. J. Cell. Biol., 88, 352-357.
14. Horgon I. E. (1982). Total and lipid-bound sialic acid in sera from patients with cancer. Clin. Chim. Acta, 118, 327-331.
15. Humphries M. J., M. Obara, K. Olden and K. M. Yamada (1989). Role of fibronectin in adhesion, migration and metastasis. Cancer Invest., 7, 373-393.
16. Kageyama T., H. Ohyabult and S. Ohshiba (1989). Variation of plasma fibronectin levels in leukemia patients. Bull. Osaha Med. Coll., 35, 71-76.
17. Khandena U., J. Keller and B. Grossman (1983). Serum sialic acid is a biological marker for malignant disease. J. Surg. Oncol., 23, 163-166.
18. Kharrasov A. F., N. A. Safina, I. P. Moroz and O. F. Zinkevich (1991). Level of plasma fibronectin and its biological activity in patients with ovarian cancer. Vopr. Onkol., 37, 572-576.
19. Lehninger A. L. (1975). Biochemistry, 2 Ed., Worth, New York, pp. 650-651.
20. Lloyd C. W. (1975). Sialic acid and the social behaviour of cells. Biol. Rev., 50, 325-350.
21. Lowry O. H., N. J Rosebrough, A. C. Farr and R. J. Randall (1951). Protein measurement with the folin phenol reagent. J Biol. Chem., 193, 265.
22. Mosesson M. W. and D. L. Amrani (1980). The structure and biological activities of plasma fibronectin. Blood, 56, 145-158.
23. Mosher D. F. (1980). Progress in hemostasis and thrombosis. Vol. 5. Grune and Stratton, New York, pp. 111-151.
24. Mosher D. F. and E. M. Williams (1978). Fibronectin concentration is decreased in plasma of severely ill patients with disseminated intravascular coagulation. J. Lab. Clin. Med., 91, 729-735.
25. Murty M. S., E. F. Scanlon, R. H. Silverman, C. R. Goodheart, R. A. Goldschmidt and M. L. Jelachich (1993). The role of fibronectin in tumor implantation at surgical sites. Clin. Exp. Metastasis, 11, 159-173.
26. Oh E., M. Pierschbacher and E. Ruoslahti (1981). Deposition of plasma fibronectin in tissues. Proc. Natl. Acad. Sci. USA, 78, 3218-3221.
27. Özyurt E., H. Sönmez, S. Süer and E. Kökoǧlu (1996). The prognostic importance of fibronectin and sialic acid levels in human pituitary adenomas. Cancer Lett., 100, 151-154.
28. Pluncinsky M., M. Riley, J. Prorok and J. Alhadeff (1986). Total and lipid-associated serum sialic acid levels in cancer patients with differing degrees of metastatic involvement. Cancer, 58, 2680-2685.
29. Potazman J. P., V. Doussal, J. Pouillard, L. Jallais and J. L. Robert (1988). Plasma fibronectin in mammary and uterine carcinomas. Clin. Physiol. Biochem., 6, 12-20.
30. Reed R. G., J. U. Gutterman, G. M. Mavligit and E. M. Hersh (1974). Sialic acid on leukemia cells: relation to morphology and tumor immunity. Proc. Soc. Exp. Biol. Med., 145, 790-793.
31. Ronquist G. and E. Nov (1983). Serum sialy transferase and fucosyltransferase activities in patients with bronchial carcinoma. Cancer, 52, 1674-1683.
32. Saba T. M., F. A. Blumenstoch, W. A. Scovill and H. Bernard (1978). Cryoprecipitate reversal of opsonic 2-surface binding glycoprotein deficiency in septic, surgical and trauma patients. Science, 201, 622-624.
33. Schutter E. M., J. J. Visser, G. S. van-Kamp, P. S. Mensdorff, W. Van-Dijk, J. Hilgers and P. Kenemans (1992). The utility of lipid-associated sialic acid as a serum marker for malignancy. Tumor Biol., 13, 121-132.
34. Shamberger R. J. (1984). Serum sialic acid in normals and in cancer patients. J. Clin. Chem. Clin. Biochem., 22, 647-651.
35. Silver H., D. Rangel and D. Morton (1978). Serum sialic acid elevations in malignant melanoma patients. Cancer, 41, 1497-1499.
36. Simmons R. L. and A. Rios (1974). Cell surface modification in the treatment of experimental cancer; neuraminidase or concanavalin A. Cancer, 34, 1541-1547.
37. Singhal A. and S. Hakomori (1990). Molecular changes in carbohydrate antigens associated with cancer. Bioassays, 12, 223-230.
38. Siri A., B. Carnemulla, P. Castellani, E. Balza, S. Raffanti and L. Zardi (1983). Increased plasma fibronectin concentrations in tumor bearing mice. Cancer Lett., 21, 117-123.
39. Siri A., B. Carnemolla, S. Raffanti, P. Castellani, E. Balzono and L. Zordi (1984). Fibronectin concentration in pleural effusions patients with malignant and non-malignant diseases. Cancer Lett., 22, 1-9.
40. Sönmez H., E. Kökoǧlu, S. Süer and E. Özyurt (1995a). Fibronectin and sialic acid levels in human meningiomas and gliomas. Cancer Lett., 90, 119-122.
41. Sönmez H., S. Süer, I. Karaarslan, H. Baloǧlu and E. Kökoǧlu (1995b). Tissue fibronectin levels of human prostatic cancer, as a tumor marker. Cancer Biochem. Biophys., 15, 10-110.
42. Süer S., H. Sonmez, I. Karaarslan, H. Baloǧlu and E. Kökoǧlu (1996) Tissue sialic acid and fibronectin levels in human prostatic cancer. Cancer Lett., 99, 135-137.
43. Vahen A and D. F Mosher (1978) High molecular weight, cell surface associated alycoprotein (fibronectin) lost in malignant transformation. Biochim. Biophys. Acta, 516, 1-25.
44. Van Beek W. P., L. A. Smets and P. Emmelot (1973). Increased sialic acid density in surface glycoprotein of transformed and malignant cells-a general phenomenon? Cancer Res., 33, 2913-2922.
45. Warren L. (1959). The thiobarbituric acid assay of sialic acids. J. Biol. Chem., 234, 1971-1975.
46. Webb K. and G. Lin (1980). Urinary tibronectin. Potential as a biomarker in prostatic cancer. Invest. Urol , 17, 401-404.
47. Weiss J. F., R. A. Morantz, W. P. Bradley and P. B. Chretien (1979), Serum acute-phase proteins and immunoglobulins in patients with gliomas. Cancer Res , 39, 542-544